A patient with a TIL-high, PD-L1-positive, interferon-gamma-rich tumor may proceed directly to combination checkpoint blockade, whereas a patient with a non-inflamed tumor might first receive an oncolytic virus or an epigenetic modifier such as an HDAC inhibitor to prime the tumor for immunotherapy [65]. The gene discussed is IFNG; the disease is neoplasm.